Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J HIRSH

Showing results (391-400 of 666) with videos related to

Pageof 67
Sort By:
The American Journal of Medicine|March 1, 1996
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysisS Siragusa, B Cosmi, F Piovella, et al.
Chest|February 1, 1989
Optimal therapeutic range for oral anticoagulantsJ Hirsh, L Poller, D Deykin, et al.
Thrombosis Research|February 15, 1986
Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin IIIJ R Leclerc, W Geerts, A Panju, et al.
Blood|February 1, 1977
Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosisH M Chiu, J Hirsh, W L Yung, et al.
Thrombosis and Haemostasis|July 6, 1992
The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat modelP Klement, A Borm, J Hirsh, et al.
Transplantation|April 1, 1992
The effect of high-dose nifedipine on renal hemodynamics of cyclosporine-treated renal allograft recipientsA Chagnac, D Zevin, Y Ori, et al.
Thrombosis Et Diathesis Haemorrhagica|November 15, 1975
Proceedings: Platelet survival, fibrinolytic activity, antithrombin II (AT III) level and fibrinogen survival in venous thromboembolism (VTE)A S Gallus, I R Walker, J Hirsh, et al.
British Journal of Haematology|February 1, 1989
Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphationJ Van Ryn-McKenna, F A Ofosu, J Hirsh, et al.
American Journal of Clinical Pathology|February 1, 1991
Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapyJ Ansell, C Tiarks, J Hirsh, et al.
The Journal of Laboratory and Clinical Medicine|January 9, 1998
The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearanceL Manson, J I Weitz, T J Podor, et al.
Pageof 67

Showing results (391-400 of 666) with videos related to

Sort By:
Pageof 67
The American Journal of Medicine|March 1, 1996
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysisS Siragusa, B Cosmi, F Piovella, et al.
Chest|February 1, 1989
Optimal therapeutic range for oral anticoagulantsJ Hirsh, L Poller, D Deykin, et al.
Thrombosis Research|February 15, 1986
Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin IIIJ R Leclerc, W Geerts, A Panju, et al.
Blood|February 1, 1977
Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosisH M Chiu, J Hirsh, W L Yung, et al.
Thrombosis and Haemostasis|July 6, 1992
The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat modelP Klement, A Borm, J Hirsh, et al.
Transplantation|April 1, 1992
The effect of high-dose nifedipine on renal hemodynamics of cyclosporine-treated renal allograft recipientsA Chagnac, D Zevin, Y Ori, et al.
Thrombosis Et Diathesis Haemorrhagica|November 15, 1975
Proceedings: Platelet survival, fibrinolytic activity, antithrombin II (AT III) level and fibrinogen survival in venous thromboembolism (VTE)A S Gallus, I R Walker, J Hirsh, et al.
British Journal of Haematology|February 1, 1989
Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphationJ Van Ryn-McKenna, F A Ofosu, J Hirsh, et al.
American Journal of Clinical Pathology|February 1, 1991
Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapyJ Ansell, C Tiarks, J Hirsh, et al.
The Journal of Laboratory and Clinical Medicine|January 9, 1998
The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearanceL Manson, J I Weitz, T J Podor, et al.
Pageof 67